RZLTRezolute, Inc.

Healthcare
$4.64-47% 1Y

The financials

Rezolute, Inc. by the numbers

The next results filing is expected around Dec 24, 2026, a quarter after the last one.

Rezolute, Inc. income statement, Q4 2026 against the same quarter a year earlier
Income statementQ4 2026Q4 2025Change
Operating income−$22M−$26Mn/a
Net income−$20M−$24Mn/a
Diluted EPS−$0.20−$0.26n/a

Biotechnology

Ranks #168 of 196 by RyuScore

Compare peers
AGMB+3.1%
Agomab Therapeutics NV
PRTA+1.5%
PROTHENA CORP PUBLIC LTD CO
ASMB-0.74%
ASSEMBLY BIOSCIENCES, INC.
SPRY+5.1%
ARS Pharmaceuticals, Inc.
OVID-0.64%
Ovid Therapeutics Inc.
EDIT+3.3%
Editas Medicine, Inc.